Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | STS | P08842 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772899 | 0.95 | LIMK2 (0.48) | LIMK2TGFBR1GPR119STSMMP13 | |
| SCHEMBL24628229 | 0.95 | LIMK2 (0.48) | LIMK2TGFBR1GPR119STSMMP13 | |
| SCHEMBL23355023 | 0.85 | LIMK2 (0.53) | LIMK2TGFBR1GPR119STSMMP13 | |
| SCHEMBL30936612 | 0.82 | HTR2A (0.50) | — | |
| SCHEMBL29772863 | 0.82 | NPY2R (0.52) | LIMK2GPR119NPY2R | |
| SCHEMBL24628372 | 0.82 | NPY2R (0.52) | LIMK2GPR119NPY2R | |
| SCHEMBL23355043 | 0.82 | MCOLN3 (0.50) | LIMK2TGFBR1GPR119STS | |
| SCHEMBL31720603 | 0.81 | MCOLN2 (0.49) | — | |
| SCHEMBL24628795 | 0.80 | MCOLN2 (0.42) | NPY2R | |
| SCHEMBL29772864 | 0.80 | MCOLN2 (0.42) | NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4608389-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | Nine Square Therapeutics Corporation (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024092235-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2024-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | TRPM2, TRPM6, TRPM5 | LIMK2 387/4885TGFBR1 3720/4885GPR119 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.